Physician profile
Stephanie Cimo
NPI 1194105668
$1,057.90
in general payments reported to CMS, 2019-2025
16 companies · $607 in 2025
The $607 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.67 · 2023: $99.54 · 2024: $303 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.24 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $429.90 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $163.08 | 2024-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $66.59 | 2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $51.59 | 2019-2025 | |
| Janssen Biotech, INC. | $48.19 | 2025 | Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $45.52 | 2023-2025 | |
| Emd Serono, INC. | $40.47 | 2025 | |
| Tersera Therapeutics LLC | $31.99 | 2025 | Zoladex |
| Incyte Corporation | $30.52 | 2019 | |
| Genentech USA, INC. | $26.79 | 2025 | Polivy |
| Geron Corporation | $26.62 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $23.57 | 2025 | Fruzaqla |
| Novartis Pharmaceuticals Corporation | $22.06 | 2025 | |
| Pfizer INC. | $19.94 | 2025 | |
| Gilead Sciences, INC. | $17.33 | 2025 | Trodelvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $13.74 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Cimo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.